[Federal Register Volume 74, Number 199 (Friday, October 16, 2009)]
[Notices]
[Pages 53265-53267]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-24871]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Biological/Research Material for H1N1 Influenza Virus Vaccine Research
Description of Technology: Offered for licensing is a recombinant
attenuated vaccinia virus, MVA, that expresses the haemagglutinin (HA)
and nucleoprotein (NP) of influenza virus A/PR/8/34 (H1N1). The virus
has been shown to stimulate protective immunity to influenza virus in
mice.
The materials can be used for research purposes and in particular
in the area of influenza virus vaccines.
The related publications listed below demonstrate the usefulness of
this biological material in influenza virus vaccine research.
Applications: Research reagents useful in research and development
in the area of H1N1 Influenza virus vaccines.
Development Status: Fully developed. The usefulness of the
materials has been shown in Dr. Moss' laboratory.
[[Page 53266]]
Inventors: Bernard Moss and Linda S. Wyatt (NIAID).
Publications:
1. G Sutter, LS Wyatt, PL Foley, JR Bennink, B Moss. A recombinant
vector derived from the host range-restricted and highly attenuated MVA
strain of vaccinia virus stimulates protective immunity in mice to
influenza virus. Vaccine 1994 Aug;12(11):1032-1040.
2. B Bender, CA Rowe, SF Taylor, LS Wyatt, B Moss, PA Small Jr.
Oral immunization with a replication-deficient recombinant vaccinia
virus protects mice against influenza. J Virol. 1996 Sep;70(9): 6418-
6424.
Patent Status: HHS Reference No. E-260-2009/0--Research Material.
Patent protection is not being sought for this technology.
Related Technologies: HHS Reference No. E-552-1982/2--
1. U.S. Patent No. 6,998,252 issued 14 Feb 2006, ``Recombinant
Poxviruses Having Foreign DNA Expressed Under the Control of Poxvirus
Regulatory Sequences''
2. U.S. Patent No. 7,015,024 issued 21 Mar 2006, ``Compositions
Containing Poxviruses Having Foreign DNA Expressed Under the Control of
Poxvirus Sequences''
3. U.S. Patent No. 7,045,313 issued 16 May 2006, ``Recombinant
Vaccinia Virus Containing Chimeric Gene Having Foreign DNA Flanked by
Vaccinia Regulatory DNA''
4. U.S. Patent No. 7,045,136 issued 16 May 2006, ``Methods of
Immunization Using Recombinant Poxviruses Having Foreign DNA Expressed
Under the Control of Poxvirus Regulatory Sequences''
An abstract describing these technologies may be viewed at http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=2000.
Licensing Status: Available for licensing.
Licensing Contacts: Uri Reichman, Ph.D., MBA; 301-435-4616;
[email protected]; RC Tang, JD, LLM; 301-435-5031; [email protected].
Biological/Research Material for HIV Vaccine Research
Description of Technology: Offered for licensing is a recombinant
attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The
materials can be used for research purposes and in particular in the
area of HIV/AIDS vaccines.
Plasmid insertion vector pJH-4, containing the foreign gene SIV 239
GagPol controlled by vaccinia early/late promoter, inserts into del III
of attenuated vaccinia MVA virus to make recombinant MVA virus. The
resulting recombinant virus made from pJH4, MVA/SIV239gagpol, expresses
the SIV 239gagpol gene and thus can be used to conduct vaccine studies
in animal models such as Rhesus macaques.
The list of publications shown below demonstrates the usefulness of
this biological material in HIV vaccine research.
Applications: Research reagents useful in research and development
in the area of HIV/AIDS vaccines.
Development Status: Fully developed. Material has been used
extensively in research.
Inventors: Bernard Moss and Linda S. Wyatt (NIAID).
Publications:
1. RR Amara, F Villinger, JD Altman, SL Lydy, SP O'Neil, SI
Staprans, DC Montefiori, Y Xu, JG Herndon, LS Wyatt, MA Candido, NL
Kozyr, PL Earl, JM Smith, HL Ma, BD Grimm, ML Hulsey, J Miller, HM
McClure, JM McNicholl, B Moss, HL Robinson. Control of a mucosal
challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
Science 2001 Apr 6;292(5514):69-74.
2. PL Earl, LS Wyatt, DC Montefiori, M Bilska, R Woodward, PD
Markbam, JD Malley, TU Vogel, TM Allen, DI Watkins, N Miller, B Moss.
Comparison of vaccine strategies using recombinant env-gag-pol MVA with
or without an oligomeric Env protein boost in the SHIV rhesus macaque
model. Virology 2002 Mar 15;294(2):270-281.
3. RR Amara, JM Smith, SI Staprans, DC Montefiori, F Villinger, JD
Altman, SP O'Neil, NL Kozyr, Y Xu, LS Wyatt, PL Earl, JG Herndon, JM
McNicholl, HM McClure, B Moss, HL Robinson. Critical role for Env as
well as Gag-Pol in control of a simian-human immunodeficiency virus
89.6P challenge by a DNA prime/recombinant modified vaccinia virus
Ankara vaccine. J Virol. 2002 Jun;76(12):6138-6146.
4. RR Amara, F Villinger, SI Staprans, JD Ahman, DC Montefiori, NL
Kozyr, Y Xu, LS Wyatt, PL Earl, JG Herndon, HM McClure, B Moss, HL
Robinson. Different patterns of immune responses but similar control of
simian human immunodeficiency virus 89.6P mucosal challenge by modified
vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol. 2002
Aug;76(15):7625-7631.
5. S Sadagopal, RR Amara, DC Montefiori, LS Wyatt, SI Staprans, NL
Kozyr, HM McClure, B Moss, HL Robinson. Signature for long-term
vaccine-mediated control of a Simian and human immunodeficiency virus
89.6P challenge: stable low-breath and low-frequency T-cell response
capable of coproducing gamma interferon and interleukin-2. J Virol.
2005 Mar;79(6):3243-3253.
Patent Status: HHS Reference No. E-258-2009/0--Research Material.
Patent protection is not being pursued for this technology.
Related Technologies: HHS Reference No. E-552-1982/2--
1. U.S. Patent No. 6,998,252 issued 14 Feb 2006, ``Recombinant
Poxviruses Having Foreign DNA Expressed Under the Control of Poxvirus
Regulatory Sequences''
2. U.S. Patent No. 7,015,024 issued 21 Mar 2006, ``Compositions
Containing Poxviruses Having Foreign DNA Expressed Under the Control of
Poxvirus Sequences''
3. U.S. Patent No. 7,045,313 issued 16 May 2006, ``Recombinant
Vaccinia Virus Containing Chimeric Gene Having Foreign DNA Flanked by
Vaccinia Regulatory DNA''
4. U.S. Patent No. 7,045,136 issued 16 May 2006, ``Methods of
Immunization Using Recombinant Poxviruses Having Foreign DNA Expressed
Under the Control of Poxvirus Regulatory Sequences''
An abstract describing these technologies may be viewed at http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=2000.
Licensing Status: Available for licensing.
Licensing Contacts: Uri Reichman, Ph.D., MBA; 301-435-4616;
[email protected]; RC Tang, JD, LLM; 301-435-5031; [email protected].
A Target for the Development of Diagnostics and Therapeutics for
Abnormal Hematopoiesis
Description of Technology: The zinc finger protein ZFP36L2 has been
shown by the inventors to play an essential role in hematopoiesis, a
process that is dysregulated in hematological cancers, anemia, and
other conditions. Thus, ZFP36L2 has promise for use in a diagnostic
test to detect abnormal hematopoiesis, or as a target for the
development of therapeutics to treat abnormal hematopoiesis.
Hematopoiesis is the formation of blood cellular components,
through the differentiation of hematopoietic stem cells into lineages
with a variety of roles, such as carrying oxygen, immune function, and
blood clotting. Abnormally high hematopoiesis can be caused by
hematological cancers such as leukemia or lymphoma, or by other
myeloproliferative disorders. Abnormally low hematopoiesis can be
caused by diseases such as anemia, thrombocytopenia, or myelodysplastic
syndrome, and is often a secondary symptom of other conditions, such as
cancer, infection, or dialysis.
[[Page 53267]]
The inventors have discovered that Zinc finger protein 36 like
type-2 (ZFP36L2) plays an essential role in hematopoiesis, possibly by
affecting the stability of mRNAs involved in this process. ZFP36L2 is a
member of the tristetraprolin (TTP) family, which are mRNA-binding
proteins involved in mRNA processing and degradation. The invention
discloses methods of detecting abnormal hematopoiesis by detecting
abnormal ZFP36L2 expression or a mutation in the ZFP36L2 gene, and
methods of controlling abnormal hematopoiesis by modulating levels of
ZFP36L2 protein.
Applications:
Diagnostic test to detect abnormal hematopoiesis.
Therapy for abnormal hematopoiesis.
Development Status: Discovery stage.
Market:
Over 3.5 million people in the United States suffer from
anemia, according to NHLBI, and more than half of all chemotherapy
treatment for cancer results in anemia.
The American Cancer Society estimates that approximately
4300 cases of chronic myelogenous leukemia are diagnosed in the United
States every year.
Inventors: Perry J. Blackshear and Deborah J. Stumpo (NIEHS).
Related Publication: DJ Stumpo, HE Broxmeyer, T Ward, S Cooper, G
Hangoc, YJ Chung, WC Shelley, EK Richfield, MK Ray, MC Yoder, PD Aplan,
PJ Blackshear. Targeted disruption of Zfp36l2, encoding a CCCH tandem
zinc finger RNA-binding protein, results in defective hematopoiesis.
Blood 2009 Sep 17;114(12):2401-2410.
Patent Status: PCT Application Serial No. PCT/US08/68900 filed on
01 Jul 2008 (HHS Reference No. E-255-2007/0-PCT-02).
Licensing Status: Available for licensing.
Licensing Contact: Tara Kirby, Ph.D.; 301-435-4426;
[email protected].
Collaborative Research Opportunity: The NIEHS Laboratory of Signal
Transduction, Polypeptide Hormone Action Group, is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize this
technology. Please contact Elizabeth M. Denholm, Ph.D., Director,
Office of Technology Transfer, NIEHS, at [email protected] for
more information.
Susceptibility-Matched Multiwell Plates for High-Throughput Screening
by Magnetic Resonance Imaging and Nuclear Magnetic Resonance
Spectroscopy
Description of Technology: Available for licensing and commercial
development is a patent estate that covers multi-well assay plates for
high-throughput screening by magnetic resonance imaging (MRI) and
nuclear magnetic resonance (NMR) spectroscopy. Multi-well plates are
used in a wide variety of high-throughput measurements in clinical
chemistry and immunology, as well as in drug discovery and other
research applications. Magnetic resonance imaging (MRI) of multi-well
plates offers the possibility of performing new kinds of high-
throughput assays, including the detection of magnetic nanoparticles
attached to or within cells. Moreover, MRI-guided localized nuclear
magnetic resonance (NMR) spectroscopy could be used to perform detailed
chemical analysis of complex mixtures of metabolites not possible by
any other common analytical technique. Best of all, conventional MRI
techniques exist which would permit all samples in one or more multi-
well plate(s) to be analyzed simultaneously. Unfortunately,
conventional multi-well plates typically give poor performance for MRI-
based assays since they provide inadequate matching of magnetic
susceptibility between the plate, the sample and their surroundings.
This results in distortion of the magnetic field within the scanner and
thus reduces the sensitivity for detecting magnetic particles and the
resolution of NMR spectra.
This invention relates to a new multi-well plate design
incorporating one-piece polyetherimide plastic construction for
improved magnetic susceptibility matching for aqueous samples. This
design can easily be extended to non-aqueous samples by the selection
of an appropriate, commercially available plastic resin or resin blend.
Further enhancement in susceptibility matching can be accomplished by
combining the new plate design with plugs for each well constructed
from the same plastic as the plate. These plugs would allow the entire
thickness of each sample to be scanned in chemical analyses, improving
signal-to-noise ratio and sensitivity. These plugs can optionally be
integrated into a single ``cap mat'' so that the entire assembly can be
filled and manipulated by standard robotic laboratory equipment already
in wide use in the pharmaceutical industry. Alternatively, spherical
wells, accessed by narrow fill holes, may be molded into a solid plate,
eliminating the need for individual plugs to seal each well. The new
multi-well plate/plug design reduces magnetic field distortions and
should dramatically improve spectral resolution and sensitivity for NMR
and MRI-based high-throughput screening.
Applications:
NMR Spectroscopy,
MRI Imaging of magnetic nanoparticles,
Clinical Chemistry,
Immunology,
Drug Discovery,
Combinatorial Chemistry, and
Quality Control in the pharmaceutical, chemical and
agricultural industries.
Advantages:
Increased signal-to-noise ratio and sensitivity relative
to conventional multi- well plates
Portability
Compatible with existing high-throughput robots.
Development Status: Used actively in inventor's lab.
Inventor: Kenneth W Fishbein (NIA).
Patent Status: U.S. Patent Application No. 12/083,501 filed 30 Dec
2008 (HHS Reference No. E-243-2005/0-US-03).
Licensing Status: Available for licensing.
Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019;
[email protected].
Collaborative Research Opportunity: The National Institute on
Aging, Magnetic Resonance Imaging & Spectroscopy Section, is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
this technology. Please contact Nicole Darack, Ph.D. at 301-435-3101 or
[email protected] for more information.
Dated: October 5, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E9-24871 Filed 10-15-09; 8:45 am]
BILLING CODE 4140-01-P